Loading company…
Martinsried-based biotech developing cancer immunotherapies, including TCR-modified T cells and dendritic cell vaccines.
Founded in 1994 and based in Martinsried, Germany, MediGene AG is a biotechnology company developing immunotherapies for cancer, including TCR-modified T cells and dendritic cell vaccines. In 1998, Atlas Venture, Bankhaus Vontobel, Deutsche Bank, Dresdner Bank and Merifin Capital completed a USD 26 million series C round. It completed an initial public offering of 2.6 million shares at EUR 39.65 each in 2000.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in